• The need to regularly assess the fundus
• Neovascular, uveitic, or malignant glaucoma
20%–25% C
• Sulfonamide allerg y
• Kidney stones
• Aplastic anemia
• Thrombocytopenia
• Sickle cell disease
15%–20% C
20%–30%
• Renal failure
• CHF
No data C
a
Data from the Heijl A, Traverso CE, eds. Terminolog y and Guidelines for Glaucoma. European
Glaucoma Society. 4th ed. Savona, Italy: PubliComm; 2014:146-51. Available at: www.eugs.org/
eng/EGS_guidelines4.asp. Accessed May 29, 2015.
b
FDA Pregnancy Category B =Animal reproduction studies have failed to demonstrate a risk to the
fetus and there are no adequate and well-controlled studies on pregnant women. FDA Pregnancy
Category C = Animal reproduction studies have shown an adverse effect on the fetus and there are
no adequate and well-controlled studies in humans, but potential benefits may warrant use of the
drug in pregnant women despite potential risks.
Potential Contraindications IOP Reduction
a
FDA Pregnancy
Safety Category
b
13
